About GRAIL
GRAIL is a company based in Menlo Park (United States) founded in 2016 was acquired by Illumina in September 2020. GRAIL has raised $3.22 billion across 8 funding rounds from investors including Merck, Amazon and Tencent. The company has 1,000 employees as of December 31, 2024. GRAIL offers products and services including Galleri Test. GRAIL operates in a competitive market with competitors including Guardant Health, Color, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others.
- Headquarter Menlo Park, United States
- Employees 1000 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Grail, Inc.
-
Annual Revenue
$125.59 M (USD)34.9as on Dec 31, 2024
-
Net Profit
-$2.03 B (USD)-38.3as on Dec 31, 2024
-
EBITDA
-$569.7 M (USD)10.74as on Dec 31, 2024
-
Total Equity Funding
$3.22 B (USD)
in 8 rounds
-
Latest Funding Round
$110 M (USD), Post-IPO
Jun 25, 2026
-
Investors
Merck
& 32 more
-
Employee Count
1000
as on Dec 31, 2024
-
Acquired by
Illumina
(Sep 20, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of GRAIL
GRAIL is a publicly listed company on the NASDAQ with ticker symbol GRAL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of GRAIL
GRAIL offers a comprehensive portfolio of products and services, including Galleri Test.
Blood test for detecting multiple cancers early through DNA analysis.
People of GRAIL
Unlock access to complete
Unlock access to complete
Funding Insights of GRAIL
GRAIL has successfully raised a total of $3.22B across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $110 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GRAIL
GRAIL has secured backing from 33 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Merck, Amazon and Tencent.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and hedge fund investments in healthcare are managed.
|
Locked | Locked | Locked | |
|
Global private equity investments are managed with long-term focus.
|
Locked | Locked | Locked | |
|
Life-Sciences focused early and growth stage VC firm funding companies in China & the US
|
Locked | Locked | Locked |
Investor details for GRAIL
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GRAIL
Investment portfolio details for GRAIL
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GRAIL
Detailed financials for GRAIL
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Grail Comparisons
Peer comparison for GRAIL
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GRAIL
GRAIL operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Color, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Cancer care is delivered through a virtual clinic by Color.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
|
| Locked | Locked | Locked |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
Detailed competitors of GRAIL
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Grail
Complete news archive for GRAIL
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GRAIL
GRAIL was founded in 2016.
GRAIL is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Bob Ragusa is the current CEO of GRAIL.
GRAIL is a funded company, having raised a total of $3.22B across 8 funding rounds to date.
As of Dec 31, 2024, the latest employee count at GRAIL is 1,000.
Annual revenue of GRAIL is $125.59M as on Dec 31, 2024.
GRAIL was founded in 2016 in Menlo Park, United States, within the biotechnology sector focused on oncology. A platform for screening circulating tumor DNA to enable cancer detection is operated by the company. The Galleri test, designed as a pan-cancer screening tool, is developed by analyzing circulating nucleic acids from blood samples. Ultra-deep sequencing techniques are employed in this proprietary platform to quantify tumor DNA levels in patients.
GRAIL's top competitors include Guardant Health, BillionToOne and Delfi Diagnostics.
GRAIL offers Galleri Test.
Yes, GRAIL is publicly traded on NASDAQ under the ticker symbol GRAL.
The ticker symbol of GRAIL is GRAL on NASDAQ.